411
Participants
Start Date
July 6, 2011
Primary Completion Date
March 2, 2012
Study Completion Date
March 2, 2012
Evolocumab
Administered by subcutaneous injection
Ezetimibe
Administered orally once a day
Placebo to Evolocumab
Administered by subcutaneous injection
Research Site, Linkebeek
Research Site, Maroubra
Research Site, Retie
Research Site, Ballerup Municipality
Research Site, Halen
Research Site, Ham
Research Site, Carina Heights
Research Site, Anthée
Research Site, Gozée
Research Site, Gribomont
Research Site, Vejle
Research Site, Dour
Research Site, Aalborg
Research Site, New Windsor
Research Site, Endwell
Research Site, Duncansville
Research Site, Bethesda
Research Site, Richmond
Research Site, Norfolk
Research Site, Raleigh
Research Site, Raleigh
Research Site, Mt. Pleasant
Research Site, Decatur
Research Site, Ponte Vedra
Research Site, Jacksonville
Research Site, Jacksonville
Research Site, DeLand
Research Site, Sanford
Research Site, Miami
Research Site, Miami
Research Site, Birmingham
Research Site, Louisville
Research Site, Cleveland
Research Site, Cincinnati
Research Site, Cincinnati
Research Site, Indianapolis
Research Site, Brooklyn Center
Research Site, Rapid City
Research Site, Fargo
Research Site, Chicago
Research Site, Little Rock
Research Site, Norman
Research Site, Oklahoma City
Research Site, Arlington
Research Site, Boerne
Research Site, San Antonio
Research Site, Las Vegas
Research Site, Inglewood
Research Site, Encinitas
Research Site, San Diego
Research Site, Tustin
Research Site, Renton
Research Site, Seattle
Research Site, Brockton
Research Site, Bay Roberts
Research Site, Mount Pearl
Research Site, Toronto
Research Site, Granby
Lead Sponsor
Amgen
INDUSTRY